Wednesday, Nuvation Bio Inc. (NUVB) announced that the U.S. Food and Drug Administration has accepted a supplemental New Drug Application with updated data for IBTROZI for the treatment of advanced ROS1-positive non-small cell lung cancer, with a target action date of January 4, 2027.
The submission includes an additional 10 months of data from the pivotal TRUST-I and TRUST-II studies as of an August 2025 data cutoff, further validating the overall clinical profile with long-term follow-up.
These findings revealed that IBTROZI demonstrated a median duration of response of 49.7 months and a median progression-free survival of 49.6 months in TKI-naïve patients in TRUST-I. However, the median duration of response had not yet been reached in TKI-naïve patients in the TRUST-II study at the time of the data cutoff.
In the pre-market hours, NUVB is trading at $4.90, up 1.87 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.